TOVX
Theriva Biologics, Inc.stockNYSEAMERICAN
synthetic biologics, inc. (nyse mkt: syn) is a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients. the company's lead candidates poised for phase 3 development are: (1) syn-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (ibs-c), and (2) syn-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (iv) beta-lactam antibiotics for the prevention of c. difficile infection (cdi), antibiotic-associated diarrhea (aad) and the emergence of antimicrobial-resistance (amr). the company is also developing preclinical stage monoclonal antibody therapies for the prevention and treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria (pku).
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.16 | 2026-11-12 | -6.88% | -0.446 |
| 1M | 0.20 | 2026-10-19 | -27.21% | 1.877 |
| 3M | 0.23 | 2026-08-19 | -33.90% | 1.714 |
| 6M | 0.27 | 2026-05-19 | -44.17% | 1.853 |
| 1Y | 0.23 | 2025-11-19 | -35.30% | 2.502 |
| 2Y | 1.26 | 2024-11-19 | -88.17% | — |
| 5Y | 25.76 | 2022-10-13 | -99.42% | 0.927 |
Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) stock price today is $0.15, and today's volume is 550,843. TOVX is up 6.429% today. The 30 day average volume is 3.71M. TOVX market cap is $6.84M with 45.89M shares outstanding.